Holen Sie sich die Stockscreener-App
1.60
3.23%
0.05
Handel nachbörslich:
1.60
Schlusskurs vom Vortag:
$1.55
Offen:
$1.56
24-Stunden-Volumen:
66,063
Relative Volume:
2.27
Marktkapitalisierung:
$9.78M
Einnahmen:
$93.76M
Nettoeinkommen (Verlust:
$-13.68M
KGV:
-0.1558
EPS:
-10.27
Netto-Cashflow:
$8.77M
1W Leistung:
-9.60%
1M Leistung:
-30.13%
6M Leistung:
-45.58%
1J Leistung:
-30.13%
1-Tages-Spanne:
$1.41
$1.6241
1-Wochen-Bereich:
$1.41
$1.97
52-Wochen-Spanne:
$1.41
$3.45
Aytu Biopharma Inc Stock (AYTU) Company Profile
Firmenname
Aytu Biopharma Inc
Sektor
Telefon
(720) 437-6580
Adresse
7900 E. UNION AVENUE, DENVER
Vergleichen Sie AYTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AYTU | 1.60 | 9.78M | 93.76M | -13.68M | 8.77M | -10.27 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Eingeleitet | H.C. Wainwright | Buy |
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com
Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks
Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com
Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch
Aytu Biopharma, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500
Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia
Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail
Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St
AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa
AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com - Investing.com South Africa
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD - Investing.com
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - Simply Wall St
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - AccessWire
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 - AccessWire
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Anterix (NASDAQ:ATEX) Sees Unusually-High Trading Volume - Defense World
Atlantica Sustainable Infrastructure (NASDAQ:AY) Now Covered by StockNews.com - Defense World
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga
Altamira Therapeutics announces pricing of $12M offering - TipRanks
Jupiter Asset Management Ltd. Makes New Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Yahoo Finance
Comparing Sanofi (NASDAQ:SNY) & Aytu BioPharma (NASDAQ:AYTU) - Defense World
Alaska Air clears hurdle in proposed merger with Hawaiian Airlines - Head Topics
Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.77 - Defense World
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 - AccessWire
Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):